Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.
about
Safety of extended treatment with anakinra in patients with rheumatoid arthritisIncidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritisSomatic mutations in the mitochondria of rheumatoid arthritis synoviocytesAutoimmune/Inflammatory Arthritis Associated Lymphomas: Who Is at Risk?Lymphoproliferative disorders in inflammatory bowel disease patients on immunosuppression: Lessons from other inflammatory disordersWhat is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis?Review article: Infliximab therapy for inflammatory bowel disease--seven years onMethotrexate-related lymphomatoid granulomatosis: a case report of spontaneous regression of large tumours in multiple organs after cessation of methotrexate therapy in rheumatoid arthritisWhole-body deletion of LPS-induced TNF-α factor (LITAF) markedly improves experimental endotoxic shock and inflammatory arthritis[Medication treatment of rheumatoid arthritis with a history of malignancy. Epidemiological data].Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence.Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary studyNon-Hodgkin's lymphoma following treatment with etanercept in ankylosing spondylitis.The National Data Bank for rheumatic diseases: a multi-registry rheumatic disease data bank.74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis.Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry.Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease.Maintenance of cytomegalovirus-specific CD4pos T-cell response in rheumatoid arthritis patients receiving anti-tumor necrosis factor treatments.Malignancy validation in a United States registry of rheumatoid arthritis patients.Methotrexate: underused and ignored?In silico discovery of potential VEGFR-2 inhibitors from natural derivatives for anti-angiogenesis therapy.The risk of cancer in patients with rheumatoid arthritis taking tumor necrosis factor antagonists: a nationwide cohort study.Etanercept: effective in the management of hidradenitis suppurativa.Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohort.Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160Etanercept in the treatment of rheumatoid arthritisThe risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials.Drug free remission after steroid-dependent disappearance of lymphoproliferative disorder in rheumatoid arthritis patient treated with TNF-alpha blockade: case study.Effects of a biologic agent in a patient with rheumatoid arthritis after treatment for methotrexate-associated B-cell lymphoma: a case report.Incidence of neoplasms in the most prevalent autoimmune rheumatic diseases: a systematic review.Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonistsRisk of lymphoma in patients with RA treated with anti-TNFalpha agents.Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas.Treating rheumatic patients with a malignancy.Why results of clinical trials and observational studies of antitumour necrosis factor (anti-TNF) therapy differ: methodological and interpretive issues.Current state of tumour necrosis factor {alpha} blockade in Wegener's granulomatosis.The British Society for Rheumatology biologics register.Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the meta-analysis by Bongartz et al
P2860
Q24675209-DA93F5AB-3996-4634-A841-042CEE176049Q24675306-D67D2BDA-D922-4A03-BDC1-52082B3BCF81Q24817118-B589B150-C481-488C-B0F5-19376C8C2929Q26739361-768845E9-EA62-437C-9B1C-CA5A8C9A35B6Q26776151-59EEE741-7027-4CD1-8F3F-1A84312F0B61Q28074148-24D97AD8-3B5D-447B-8825-FAC846CD88E8Q28294134-DA739DFA-F9EE-4609-BA06-2790D96D0152Q28299150-3FA9C8A9-14EA-4EA1-92A7-408F04B36F62Q28511199-F2E5BE4C-8659-4C11-A3EA-7EC1AC696B9EQ31036951-67CF11A6-77F9-4010-A17F-6C47522F8B60Q33346685-6CC022FF-33E2-4E8E-9B01-138DD2C73577Q33362177-96953F07-3903-44EE-B52E-AE400AD3A7C2Q33387555-5669E064-33D1-45E2-9BCE-B42DB6D31763Q33452656-08F2C5FF-02BD-4C5E-8B2B-C73E01D434B5Q34027648-6201226C-92BA-46A8-A090-FB369CFE93E7Q34077378-EC4B3236-5FA8-4041-9053-8FFBDEB8E872Q34078707-9795127F-0236-4FF5-98F3-ACA99901E667Q34152994-0D802332-73F6-4196-B85F-06317A685D17Q34287960-CEA996B0-EF91-44CB-AAF1-CE4027A61239Q34321255-E8EE3110-A579-4976-9B6C-8A61F9AF8907Q34358658-504E2AD0-5ED7-410D-883F-9E7ED0474C6FQ34363241-43D5234B-2339-48FB-AFD9-12DFF5BF9E37Q34502007-B5BE4505-6B38-4205-B650-FD5383BDA941Q34559803-9184043D-938E-4EFB-9543-38662F098028Q34628409-91CEDBB3-7BB4-4C58-8362-0CFE575A8F0BQ34637048-271B0C77-16C7-4B8A-AFE1-DD4B60713A04Q34764213-834CDF61-40CC-4931-AC33-1969F7BA9398Q34984568-46D6D679-04C6-4444-BDA7-719BD5FA8784Q35069265-19C39F12-07B9-4B42-829F-A480E569179BQ35144770-B70D0BBB-AC6E-4205-9603-9F79118888D7Q35176767-8AC82671-A2D8-4C1C-9EBF-08CE9F6B17BCQ35554823-F94E9D6F-10BB-4FFC-B92E-47239FF0E610Q35554865-68EB2B20-52F9-4939-BABB-E3007D5C76AAQ35555473-AF445E6B-602D-41C9-AA4B-050A1BE1813AQ35555527-62655A06-8976-4E1D-86D2-C3B8BC6E0E0DQ35557863-177DA400-6BC2-4DCB-BC7A-050F1B3AAFFEQ35579347-EA436431-F92E-491C-A2D5-7DD1623069E6Q35579503-3956D413-73FE-4A0D-A244-1AF5E83FA781Q35579512-D15D8D17-67FC-44FF-980F-E50124DCDA6BQ35605656-3C5BBFBD-409D-49A8-9EC2-318AB1CBAE56
P2860
Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Lymphoma in rheumatoid arthrit ...... or therapy in 18,572 patients.
@en
Lymphoma in rheumatoid arthrit ...... or therapy in 18,572 patients.
@nl
type
label
Lymphoma in rheumatoid arthrit ...... or therapy in 18,572 patients.
@en
Lymphoma in rheumatoid arthrit ...... or therapy in 18,572 patients.
@nl
prefLabel
Lymphoma in rheumatoid arthrit ...... or therapy in 18,572 patients.
@en
Lymphoma in rheumatoid arthrit ...... or therapy in 18,572 patients.
@nl
P356
P1476
Lymphoma in rheumatoid arthrit ...... or therapy in 18,572 patients.
@en
P2093
Kaleb Michaud
P304
P356
10.1002/ART.20311
P577
2004-06-01T00:00:00Z